Scancell Holdings, a developer of novel immunotherapies for the treatment of cancer, has received a key patent for its DNA ImmunoBody technology in Japan. This key patent follows approval in Australia earlier this year and adds to Scancell’s growing body of intellectual property for its ImmunoBody platform.

Scancell’s protein ImmunoBody patent has already been approved in the US, Europe, Japan and Australia.

Dr Richard Goodfellow, joint chief executive of Scancell, commented, “This Japanese approval is an important addition as we continue to build a comprehensive IP portfolio for our ImmunoBody platforms. With the positive results from our SCIB1 study announced earlier this week and the progress we are making on our Moditope programme, IP plays an increasingly important role in the value ascribed to Scancell’s technology.  We look forward to building on the momentum of Scancell’s progress in 2014.”

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope technology platforms.